Inside the deal boom: LSIPR’s five-part M&A series—all in one place

Featuring interviews with dozens of lawyers, LSIPR published a five-part deep dive into the levers driving a surge in life sciences dealmaking. Author Marisa Woutersen discovered where buyers are placing their bets, what sellers can do to make themselves 'acquisition-ready', and why IP can make or break a deal. 

Big pharma is on a buying spree. With billions of dollars chasing the next generation of drugs and technologies, what makes one company worth the bet and another too risky to touch?

That is the focus of LSIPR’s five-part series on the wave of life sciences M&A, and the role IP plays in determining which deals make it over the line.

Drawing on interviews with partners at Morrison Foerster, Polsinelli, Morgan Lewis, Dechert, Mewburn Ellis, Troutman, Freshfields and Norton Rose Fulbright, the series looks beyond the headline numbers to ask what is driving the activity, where buyers are placing their bets and what determines how much an asset is worth.

Why is 2026 already a record year for M&A activity?

By mid-2026, more than 30 acquisitions worth at least $1 billion each had been announced, with total deal value surpassing the whole of 2025 before the year was even half over.

Across biotech licensing and M&A, deal value reached $239.34 billion in the first seven months of 2026—around 60% higher than during the same period last year.

Buying the brains: Why is Big Pharma shopping for innovation?

A big factor behind the surge in biopharma deals is the looming patent cliff, with a wave of blockbuster drugs set to lose exclusivity before 2030.

As large pharma companies look to replace that revenue, many are turning outside their own pipelines for promising new products and are becoming more willing to take on external risk.

Other factors are also making deals easier to pursue. Lower biotech valuations have helped buyers and sellers reach agreement on price more quickly, while companies are increasingly targeting drugs at particular stages of development when an acquisition makes the most financial sense.

Interest is also growing in the data and AI platforms behind next-generation drug discovery, although buyers are still working out how best to value these technologies.

Where Big Pharma is betting big in the M&A boom

Demand varies considerably across therapeutic areas. Oncology remains a consistent focus for dealmaking, but obesity and metabolic disease have emerged as some of the most competitive areas of the market.

Multiple bidders and increasingly tight deal timelines are becoming common.

Buyers also face a wider strategic choice: acquire a single, more advanced drug candidate with a clearer path to near-term revenue, or invest in an entire technology platform that could produce multiple drugs over time.

China is another important part of the picture. The country has become a major source of innovation and attractive assets, while geopolitical tensions can make transactions more complicated.

The buyers' wishlist: What makes a life sciences deal stack up?

Across all deals, IP is key. Promising science may initially attract a buyer, but the strength of a company’s patents, its freedom to operate and its ownership of critical data can ultimately determine both the value of a transaction and whether it goes ahead.

As one law firm partner puts it, strong IP alone is unlikely to secure a buyer, but weak IP can cost a company one.

Built to be bought? What makes companies acquisition-ready

The final part of the series looks at what makes a biotech company genuinely ready for acquisition.

Beyond promising science, buyers want to see clean invention assignments, a well-documented development history and a management team prepared for intensive due diligence.

It is this less visible groundwork, experts say, that can separate companies buyers are ready to acquire from those they just find interesting.

Read the full series:

Part one: Why is 2026 already a record year for M&A activity?

Part two: Buying the brains: Why is Big Pharma shopping for innovation?

Part three: Where Big Pharma is betting big in the M&A boom

Part four: The buyers' wishlist: What makes a life sciences deal stack up?

Part five: Built to be bought? What makes companies acquisition-ready

Did you enjoy reading this story? Our free newsletters send stories like this straight to your inbox